Background Stroke prevention in patients with atrial fibrillation (AF) post-intracerebral haemorrhage (ICH) is an area of clinical equipoise. Little is known about the tools and processes that physicians use to make decisions regarding anticoagulation in this high-risk patient population. Objective To explore physicians' decision-making process regarding stroke prevention in patients with AF and a recent history of ICH. Method Qualitative study, utilising semi-structured interviews and analysed using Framework analysis. Results Twenty physicians from five European countries (Austria, France, Germany, Spain, United Kingdom) participated. The over-arching theme 'Managing uncertainty', addressed the process of making high-risk clinical decisio...
Background: current guidelines strongly recommend antithrombotic therapy, particularly warfarin, for...
While oral anticoagulants (OACs) are highly effective for ischemic stroke prevention in atrial fibri...
BACKGROUND: Atrial fibrillation affects 1-2% of the general population and 10% of those over 75, and...
Background Stroke prevention in patients with atrial fibrillation (AF) post-intracerebral haemorrhag...
This thesis consists of three parts. In part of A of this thesis we investigated guideline adherence...
Aims: To assess the attitudes of Australian doctors towards the use of antithrombotic drug therapy f...
Aims: To assess the attitudes of Australian doctors towards the use of antithrombotic drug therapy f...
Atrial fibrillation affects 33.5 million people worldwide and its prevalence is expected to double b...
Abstract Background and Aims It is unclear whether patients with previous intracerebral hemorrhage (...
Approximately 1 in 3-4 patients presenting with an ischemic stroke will also have atrial fibrillatio...
Abstract Background Nonvalvular atrial fibrillation (AF) is a common ongoing health problem that pla...
AbstractObjectivesAtrial fibrillation (AF) is a factor in the development of thrombi that can lead t...
Atrial fibrillation (AF) is the most common cardiac arrhythmia and poses patients at many risks. In ...
The aim of the Stroke and Atrial Fibrillation Ensemble (SAFE) II study was to identify the reasons u...
Aims: The aim of the Stroke and Atrial Fibrillation Ensemble (SAFE) II study was to identify the rea...
Background: current guidelines strongly recommend antithrombotic therapy, particularly warfarin, for...
While oral anticoagulants (OACs) are highly effective for ischemic stroke prevention in atrial fibri...
BACKGROUND: Atrial fibrillation affects 1-2% of the general population and 10% of those over 75, and...
Background Stroke prevention in patients with atrial fibrillation (AF) post-intracerebral haemorrhag...
This thesis consists of three parts. In part of A of this thesis we investigated guideline adherence...
Aims: To assess the attitudes of Australian doctors towards the use of antithrombotic drug therapy f...
Aims: To assess the attitudes of Australian doctors towards the use of antithrombotic drug therapy f...
Atrial fibrillation affects 33.5 million people worldwide and its prevalence is expected to double b...
Abstract Background and Aims It is unclear whether patients with previous intracerebral hemorrhage (...
Approximately 1 in 3-4 patients presenting with an ischemic stroke will also have atrial fibrillatio...
Abstract Background Nonvalvular atrial fibrillation (AF) is a common ongoing health problem that pla...
AbstractObjectivesAtrial fibrillation (AF) is a factor in the development of thrombi that can lead t...
Atrial fibrillation (AF) is the most common cardiac arrhythmia and poses patients at many risks. In ...
The aim of the Stroke and Atrial Fibrillation Ensemble (SAFE) II study was to identify the reasons u...
Aims: The aim of the Stroke and Atrial Fibrillation Ensemble (SAFE) II study was to identify the rea...
Background: current guidelines strongly recommend antithrombotic therapy, particularly warfarin, for...
While oral anticoagulants (OACs) are highly effective for ischemic stroke prevention in atrial fibri...
BACKGROUND: Atrial fibrillation affects 1-2% of the general population and 10% of those over 75, and...